Regeneus Ltd Stock Australian S.E.

Cambium Bio Limited is an Australia-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The Company’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. It contains enriched levels of regenerative factors, protease inhibitors, minerals and vitamins. In addition, the Company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It is also developing Sygenus, a preclinical secretome-based biologic for wound healing.